Margitta M. Retz

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Journal: Aktuelle Urologie

Published: July 24, 2026

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Journal: Cancer treatment and research communications

Published: May 03, 2026

Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus

Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus

Journal: Urologie (Heidelberg, Germany)

Published: March 05, 2026

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 21, 2026

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Journal: Cancer immunology, immunotherapy : CII

Published: February 16, 2026

Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice

Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice

Journal: Aktuelle Urologie

Published: October 27, 2025

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).

Journal: European urology oncology

Published: September 15, 2025

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Journal: European urology

Published: June 23, 2025

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 09, 2025

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 09, 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 05, 2025

Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma

Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma

Journal: Urologie (Heidelberg, Germany)

Published: November 13, 2024

Showing 1-12 of 104

Last Updated: 09/26/2026